Australia takes centre stage as a cure for Rett Syndrome draws closer

October 02, 2024 07:48 AM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

GOLD COAST, Australia, Oct. 2, 2024 /PRNewswire/ -- Australian researcher Associate Professor Wendy Gold, a world leader in Rett Syndrome research from the University of Sydney, joins international colleagues and Rett families on the Gold Coast today to present the latest advances toward a cure.


What is Rett Syndrome? Associate Professor Wendy Gold explains. Wendy will keynote the World Rett Syndrome Congress this week on the Gold Coast.

Rett Syndrome, which overwhelmingly impacts girls, is a severe genetic disorder. Affecting 1 in 10,000 female babies, sufferers begin to lose their ability to walk and talk at around 18 months of age and require lifelong 24/7 care. While girls can live into their sixties, they suffer global developmental delay and often also seizures and scoliosis.

Rett Research Australia founder, Brett Anslow, whose 11-year-old daughter Holly has Rett Syndrome, said the Australian Rett community was optimistic heading into the conference, as a cure is closer than ever before.

"Rett Syndrome is a genetic disorder, so it requires gene therapy to cure it," he said. "Wendy has done some truly extraordinary work toward a cure, as have other researchers from around the world. We feel incredibly hopeful that in the very near future there may be a cure for this absolutely devastating disorder."

Associate Professor Gold said her team were well advanced on two fronts looking at ways to cure Rett Syndrome.

"The first one is a gene editing therapy, which is looking at using what we call 'molecular scissors' to be placed in the body, to cut out the mutation in the genome and replace it with a normal copy, and we've had some exciting initial success with this," she said. "The other gene therapy we have I can't say too much about because we're actually looking at protecting it and patenting it, but it is a gene therapy similar to those that are been investigated in clinical trials, but with more regulatory control."

Associate Professor Gold and her team, along with working toward a cure, are also developing a diagnostic tool. Today there is no definitive blood test for Rett Syndrome, meaning girls are only treated once symptoms appear. Armed with a diagnostic tool, doctors would be able to treat girls with Rett Syndrome as babies, with the test potentially being able to be added to the standard newborn heel-prick test.

Associate Professor Gold points out that finding a cure for Rett Syndrome would open the floodgates for cures for other genetic diseases.

"Rett Syndrome is considered the poster child in the rare disease space, and everyone's looking at Rett syndrome, watching as they start the clinical trials. Once we have a cure it'll just open up so many options for the other disorders. There are 7, 000 rare genetic disorders, so it's encouraging to see what happens in the space for Rett syndrome.

Associate Professor Gold said her team had been able to be successful due to the tireless fundraising efforts of the Rett community. "Brett and Raelene Anslow have been absolutely central to the success we have had, by raising money for us to get to a point of success where we could then apply for grants to expand and speed up our work," she said. "90% of grant applications in Australia are unsuccessful, and it is only because we have the tireless backing of the Rett community continually fundraising and co-investing in this work, that we can continue moving forward at the pace we need to."

Rett experts from Italy, the UK, Sweden, the US, the Netherlands, Canada, Israel, France, Germany, Ireland and Scotland will join Associate Professor Gold and many Rett Syndrome families on the Gold Coast from October 2nd – 5th. For more information about Rett Syndrome or to donate, visit www.rettresearch.org.au.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.